337 related articles for article (PubMed ID: 7537123)
41. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
[TBL] [Abstract][Full Text] [Related]
42. CD34+ cells and CD34+CD38- subset from mobilized blood show different patterns of adhesion molecules compared to those from steady-state blood, bone marrow, and cord blood.
Sovalat H; Racadot E; Ojeda M; Lewandowski H; Chabouté V; Hénon P
J Hematother Stem Cell Res; 2003 Oct; 12(5):473-89. PubMed ID: 14594504
[TBL] [Abstract][Full Text] [Related]
43. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
[TBL] [Abstract][Full Text] [Related]
44. Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma.
Kobbe G; Söhngen D; Bauser U; Schneider P; Germing U; Thiele KP; Rieth C; Hünerlitürkoglu A; Fischer J; Frick M; Wernet P; Aul C; Heyll A
Ann Hematol; 1999 Oct; 78(10):456-62. PubMed ID: 10550556
[TBL] [Abstract][Full Text] [Related]
45. Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts.
Theilgaard-Mönch K; Raaschou-Jensen K; Andersen H; Russell CA; Vindeløv L; Jacobsen N; Dickmeiss E
Bone Marrow Transplant; 1999 Feb; 23(3):243-9. PubMed ID: 10084255
[TBL] [Abstract][Full Text] [Related]
46. Expression of adhesion molecules and c-kit on CD34+ hematopoietic progenitor cells: comparison of cytokine-mobilized blood stem cells with normal bone marrow and peripheral blood.
Möhle R; Haas R; Hunstein W
J Hematother; 1993; 2(4):483-9. PubMed ID: 7522108
[TBL] [Abstract][Full Text] [Related]
47. Biological characterization of CD34+ cells mobilized into peripheral blood.
Lemoli RM; Tafuri A; Fortuna A; Catani L; Rondelli D; Ratta M; Tura S
Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S47-50. PubMed ID: 9989890
[TBL] [Abstract][Full Text] [Related]
48. Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
Dercksen MW; Gerritsen WR; Rodenhuis S; Dirkson MK; Slaper-Cortenbach IC; Schaasberg WP; Pinedo HM; von dem Borne AE; van der Schoot CE
Blood; 1995 Jun; 85(11):3313-9. PubMed ID: 7538823
[TBL] [Abstract][Full Text] [Related]
49. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.
Moskowitz CH; Stiff P; Gordon MS; McNiece I; Ho AD; Costa JJ; Broun ER; Bayer RA; Wyres M; Hill J; Jelaca-Maxwell K; Nichols CR; Brown SL; Nimer SD; Gabrilove J
Blood; 1997 May; 89(9):3136-47. PubMed ID: 9129016
[TBL] [Abstract][Full Text] [Related]
50. Efflux of CD34+ cells from bone marrow to peripheral blood is selective in steady-state hematopoiesis and during G-CSF administration.
Steen R; Tjønnfjord GE; Gunnes Grøseth LA; Heldal D; Egeland T
J Hematother; 1997 Dec; 6(6):563-73. PubMed ID: 9483191
[TBL] [Abstract][Full Text] [Related]
51. Predictors for successful mobilization of peripheral blood progenitor cells with ESHAP + G-CSF in patients with pretreated non-Hodgkin's lymphoma.
Liu JH; Chen CC; Bai LY; Chao SC; Chang MS; Lin JS
J Chin Med Assoc; 2008 Jun; 71(6):279-85. PubMed ID: 18567557
[TBL] [Abstract][Full Text] [Related]
52. Correlations between hematopoietic progenitor cell counts as measured by Sysmex and CD34+ cell harvest yields following mobilization with different regimens.
Vogel W; Kopp HG; Kanz L; Einsele H
J Cancer Res Clin Oncol; 2002 Jul; 128(7):380-4. PubMed ID: 12136252
[TBL] [Abstract][Full Text] [Related]
53. Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy.
Zimmerman TM; Mick R; Myers S; Bender JG; Lee WJ; Williams SF
Bone Marrow Transplant; 1995 Jun; 15(6):923-7. PubMed ID: 7581092
[TBL] [Abstract][Full Text] [Related]
54. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin.
Brugger W; Henschler R; Heimfeld S; Berenson RJ; Mertelsmann R; Kanz L
Blood; 1994 Sep; 84(5):1421-6. PubMed ID: 7520769
[TBL] [Abstract][Full Text] [Related]
55. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
[TBL] [Abstract][Full Text] [Related]
56. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis.
Zeller W; Gutensohn K; Stockschläder M; Dierlamm J; Kröger N; Koehne G; Hummel K; Kabisch H; Weh HJ; Kühnl P; Hossfeld DK; Zander AR
Bone Marrow Transplant; 1996 May; 17(5):709-13. PubMed ID: 8733686
[TBL] [Abstract][Full Text] [Related]
57. Predictive value of the steady-state peripheral blood progenitor cell (PBPC) counts for the yield of PBPC collected by leukapheresis after mobilization by granulocyte colony-stimulating factor (G-CSF) alone or chemotherapy and G-CSF.
Husson B; Ravoet C; Dehon M; Wallef G; Hougardy N; Delannoy A
Blood; 1996 Apr; 87(8):3526-8. PubMed ID: 8605380
[No Abstract] [Full Text] [Related]
58. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer.
Burns LJ; Weisdorf DJ; DeFor TE; Repka TL; Ogle KM; Hummer C; Miller JS
Exp Hematol; 2000 Jan; 28(1):96-103. PubMed ID: 10658681
[TBL] [Abstract][Full Text] [Related]
59. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
[TBL] [Abstract][Full Text] [Related]
60. Serum G-CSF levels in patients undergoing G-CSF/chemotherapy mobilized peripheral stem cell harvest and predictors of neutrophil and platelet recovery.
Maharaj D; Gómez-Marín O; Lewis-Ximenez LL; Riley R; Albarracín C
Leukemia; 1995 Oct; 9 Suppl 1():S113-7. PubMed ID: 7475301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]